
Joan Tosca-Cuquerella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7783508/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. American Journal of Gastroenterology, 2017, 112, 120-131.	0.4	93
2	Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, caseâ€control study. Alimentary Pharmacology and Therapeutics, 2018, 47, 605-614.	3.7	57
3	Factors predicting poor prognosis in ischemic colitis. World Journal of Gastroenterology, 2006, 12, 4875-8.	3.3	52
4	Association of elevated serum triglyceride levels with a more severe course of acute pancreatitis: Cohort analysis of 1457 patients. Pancreatology, 2019, 19, 623-629.	1.1	48
5	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1492-1500.	1.3	37
6	Pathogenesis of Crohn's disease: Bug or no bug. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 1.	1.0	33
7	Minimal hepatic encephalopathy is associated with expansion and activation of CD4+CD28â^', Th22 and Tfh and B lymphocytes. Scientific Reports, 2017, 7, 6683.	3.3	30
8	Learning and Memory Impairments in Patients with Minimal Hepatic Encephalopathy are Associated with Structural and Functional Connectivity Alterations in Hippocampus. Scientific Reports, 2018, 8, 9664.	3.3	28
9	Amyloidosis in Inflammatory Bowel Disease: A Systematic Review of Epidemiology, Clinical Features, and Treatment. Journal of Crohn's and Colitis, 2016, 10, 1245-1253.	1.3	26
10	Reduced resting state connectivity and gray matter volume correlate with cognitive impairment in minimal hepatic encephalopathy. PLoS ONE, 2017, 12, e0186463.	2.5	22
11	NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved. Cells, 2021, 10, 1687.	4.1	21
12	HLA-DQ: Celiac disease <i>vs</i> inflammatory bowel disease. World Journal of Gastroenterology, 2018, 24, 96-103.	3.3	16
13	Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy. Journal of Translational Medicine, 2019, 17, 293.	4.4	16
14	Clinical outcome after antiâ€ŧumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS longâ€ŧerm study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1277-1288.	3.7	16
15	Motor and Cognitive Performance in Patients with Liver Cirrhosis with Minimal Hepatic Encephalopathy. Journal of Clinical Medicine, 2020, 9, 2154.	2.4	13
16	Longâ€term followâ€up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational caseâ€control study. United European Gastroenterology Journal, 2019, 7, 1042-1050.	3.8	12
17	Clinical evaluation of drug-induced hepatitis. Revista Espanola De Enfermedades Digestivas, 2005, 97, 258-65.	0.3	12
18	A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2021, 10, 2806.	2.4	11

#	Article	IF	CITATIONS
19	Multi-omic analysis unveils biological pathways in peripheral immune system associated to minimal hepatic encephalopathy appearance in cirrhotic patients. Scientific Reports, 2021, 11, 1907.	3.3	9
20	Could HLA-DQ Suggest Why Some Patients Have Olmesartan-Related Diarrhea and Others Don't?. American Journal of Gastroenterology, 2015, 110, 1507-1508.	0.4	8
21	Clinical assessment of risk factors for infection in inflammatory bowel disease patients. International Journal of Colorectal Disease, 2020, 35, 491-500.	2.2	8
22	Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti‶NFâ€Î±: results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2021, 53, 1021-1029.	3.7	8
23	Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. Scientific Reports, 2022, 12, 2463.	3.3	7
24	Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. International Journal of Colorectal Disease, 2019, 34, 1053-1059.	2.2	6
25	Caustic ingestion: development and validation of a prognostic score. Endoscopy, 2021, 53, 784-791.	1.8	6
26	Patients with Minimal Hepatic Encephalopathy Show Altered Thermal Sensitivity and Autonomic Function. Journal of Clinical Medicine, 2021, 10, 239.	2.4	6
27	Disease severity and treatment requirements in familial inflammatory bowel disease. International Journal of Colorectal Disease, 2017, 32, 1197-1205.	2.2	5
28	Cirrhotic patients with minimal hepatic encephalopathy have increased capacity to eliminate superoxide and peroxynitrite in lymphocytes, associated with cognitive impairment. Free Radical Research, 2018, 52, 118-133.	3.3	4
29	Oxidative and Nitrosative Pattern in Circulating Leukocytes of Very Early/Early Hepatocellular Carcinoma Patients. Anticancer Research, 2020, 40, 6853-6861.	1.1	4
30	Transjugular intrahepatic portosystemic shunt reduces hospital care burden in patients with decompensated cirrhosis. Internal and Emergency Medicine, 2021, 16, 1519-1527.	2.0	3
31	Sa1129 Fecal Incontinence (FI) in Patients With Inflammatory Bowel Disease (IBD). Probably As Important As Prevalent. Gastroenterology, 2014, 146, S-207.	1.3	2
32	P327 Evolution after a "de-intensification―strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study. Journal of Crohn's and Colitis, 2017, 11, S243-S243.	1.3	2
33	Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives. GastroenterologÃa Y HepatologÃa, 2022, 45, 383-389.	0.5	2
34	S1183 HLA Predisposing for Celiac Disease (HLA Dq2 and Dq8) Is Less Frequent in Inflammatory Bowel Disease (IBD) Patients. Preliminary Results. Gastroenterology, 2009, 136, A-208.	1.3	1
35	T1292 Association Between Early Transient Versus Persistent Organ Failure, Local Complications and Outcome in Acute Pancreatitis. Gastroenterology, 2009, 136, A-541.	1.3	1
36	Tu1926 Evolution After Anti-TNF Drug Discontinuation in Patients With Inflammatory Bowel Disease (IBD): A Multicenter Long-Term Follow-Up Study. Gastroenterology, 2016, 150, S979.	1.3	1

#	Article	IF	CITATIONS
37	Alteraciones motoras del intestino delgado. S?ndrome de pseudoobstrucci?n intestinal. Medicine, 2008, 10, 341-348.	0.0	0
38	Manejo general y extrahospitalario de los pacientes con patolog?a motora intestinal. Medicine, 2008, 10, 379-383.	0.0	0
39	W1255 Is Celiac Disease Genetic Predisposition Related to Fructose or Lactose Malabsorption in Inflammatory Bowel Disease (IBD) Patients?. Gastroenterology, 2010, 138, S-684.	1.3	Ο
40	S1097 Weekend Effect on Patients With a Nonvariceal Upper Gastrointestinal Hemorrhage (NVUGIH): Experience in a Single Teaching Hospital. Gastroenterology, 2010, 138, S-178-S-179.	1.3	0
41	Su1189 There Is a Different Tissue Transglutaminase (tTG) Distribution in Celiac Disease (CD) and Inflammatory Bowel Disease (IBD) Duodenal Mucosa. Gastroenterology, 2013, 144, S-422-S-423.	1.3	0
42	Sa1910 Family Association In Inflammatory Bowel Disease And Its Treatment Requirements. Gastroenterology, 2016, 150, S400.	1.3	0
43	Effect of Serum Triglyceride Levels on the Progress of Acute Pancreatitis. Gastroenterology, 2017, 152, S281-S282.	1.3	0
44	Minimal hepatic encephalopathy is associated with increased capacity to eliminate superoxide and peroxynitrite in lymphocytes. Journal of Hepatology, 2017, 66, S143.	3.7	0
45	HLA-DQ: Celiac Disease Versus Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S977-S978.	1.3	0
46	Caustic Ingestion: Development and Validation of a Prognostic Score. Gastroenterology, 2017, 152, S891.	1.3	0
47	Phenotypic Characteristics can Predict the Need of Adjuvant Therapy in Addition to Aminosalicylates for Maintenance of Remission in Ulcerative Colitis. Gastroenterology, 2017, 152, S753.	1.3	0
48	FRI-118-Decreased cognitive performance is associated with reduced resting state connectivity and gray matter atrophy in patients with minimal hepatic encephalopathy. Journal of Hepatology, 2019, 70, e439.	3.7	0
49	SAT-085-Selective improvement by rifaximin of changes in the inmunophenotype in patients who improve minimal hepatic encephalopathy. Journal of Hepatology, 2019, 70, e665.	3.7	0
50	P: 55 Decreased Cognitive Performance Is Associated With Reduced Resting State Connectivity and Gray Matter Atrophy in Patients With Minimal Hepatic Encephalopathy. American Journal of Gastroenterology, 2019, 114, S27-S28.	0.4	0